Home>Topics>>Exelixis Traders Brace For Upcoming FDA Decision
Exelixis Traders Brace For Upcoming FDA Decision
Healthcare Sector and Stocks Analysis from Seeking Alpha
Tue, 27 Nov 2012
By Brian L. Wilson : Many biotech traders and investors are excited, and maybe a bit anxious about the upcoming PDUFA action date for Exelixis' (NASDAQ: EXEL ) cabozantinib in the treatment of Medullary Thyroid Cancer (MTC), which is scheduled for November 29th. Due to an unexplained cancellation ...
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.